TScan Therapeutics, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, announced that it has entered into a term loan facility with...
Read Story
December 24, 2024, 07:50 AM
|
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), entered into a senior secured loan and...
Read Story
November 13, 2023, 07:50 AM
|
Mind Medicine, a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.Upon...
Read Story
August 14, 2023, 07:59 AM
|
Aptinyx, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds...
Read Story
September 16, 2021, 07:42 AM
|
VBI Vaccines announced an agreement to drawdown a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the debt financing...
Read Story
May 24, 2021, 07:00 AM
|